Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2005-06-07
2005-06-07
Mertz, Prema (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S011400, C514S012200, C514S885000, C530S324000
Reexamination Certificate
active
06902728
ABSTRACT:
The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.
REFERENCES:
patent: 9617935 (1996-06-01), None
patent: 9705896 (1997-02-01), None
patent: 9806703 (1998-02-01), None
patent: 9806751 (1998-02-01), None
Pattison et al. Rantes chemokine expression in cell-mediated transplant rejection of the kindney. The Lancet. 1994. Vol.343, pp. 209-211.
Elias et al. Structure, Function and Inhibition of Chemokines. Annual Pharmacology and Toxicology. Vol.42, pp. 469-499. 2002.
J.M. Pattison, et al., “Rantes Chemokine Expression in Transplant-Associated Accelerated Atherosclerosis”,Journal of Heart And Lung Transplantation, (Dec. 1996), 15 (12), pp. 1194-9.
H.J. Grone, et al., “Met-Rantes Reduces Vascular And Tubular Damage During Acute Renal Transplant Rejection: Blocking Monocyte Arrest And Recruitment”,FASEB Journal, (Aug. 1999) 13 (11), pp. 1371-1383.
P.J. Nelson, “Chemokines and Chemokine Receptors in Renal Transplant Rejection”,European Cytokine Network, (1999) 10/2 (305-306).
“Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers”; G. A. Bishop, et al.;Kidney International; vol. 29 (1986); pp. 708-717.
“Leukocyte-Endothelial Cell Recognition: Three (or More) Steps to Specificity and Diversity”; Eugene C. Butcher;Cell; vol. 67; Dec. 20, 1991; pp. 1033-1036.
“Lymphocyte Homing and Homeostasis”; E. Butcher, et al.;Science; vol. 272; Apr. 5, 1996; pp. 60-66.
“Acute vascular rejection: a clinical and morphological study”; M.C.R. Castro, et al.;Transpl. Int.; 1998; 11 [Suppl. 1]: S15-S18.
“Production of the RANTES Chemokine in Delayed-type Hypersensitivity Reactions: Involvement of Macrophages and Endothelial Cells”; O. Devergne, et al.;J. Exp. Med.; vol. 179; May 1994; pp. 1689-1694.
“Adhesion properties of Mono Mac 6, a monocytic cell line with characteristics of mature human monocytes”; W. Erl, et al.;Artherosclerosis; 113 (1995); pp. 99-107.
“Microvascular surgical techniques in research, with special reference to renal transplantation in the rat”; B. Fisher, et al.;Surgery; vol. 58, No. 5; Nov. 1965; pp. 904-913.
“RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors”; J. Gong, et al.;The Journal of Biological Chemistry; vol. 271, No. 18; May 3, 1996; pp. 10521-10527.
“Histopathology of the renal allograft”; H.-J. Grone;Neph. Dial. Transplant; 11; 1996; pp. 1916-1917.
“Molecular Mechanisms of Monocyte Adhesion to Interleukin-1β-Stimulated Endothelial Cells Under Physiologic Flow Conditions”; S. Kukreti, et al.;Blood; vol. 89, No. 11; Jun. 1, 1997; pp. 4104-4111.
“Rantes and Monocyte Chemoattractant Protein-1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 is Involved in Crescent Formation and Interstitial Fibrosis”; C. Lloyd, et al.;J. Exp. Med.; vol. 185, No. 7; Apr. 7, 1997; pp. 1371-1380.
“Role of MCP-1 and RANTES in inflammation and progression of fibrosis during murine crescentic nephritis”; C. Lloyd, et al.;Journal of Leukocyte Biology; vol. 62, Nov. 1997; pp. 676-680.
“Activation and regulation of chemokines in allergic airway inflammation”; N.W. Lukacs, et al.;Journal of Leukocyte Biology; vol. 59; Jan. 1996; pp. 13-17.
“L-and P-Selectins, but Not CD49d (VLA-4) Integrins, Mediate Monocyte Initial Attachment to TNF-α-Activated Vascular Endothelium Under Flow in Vitro”; F. Luscinskas, et al.;The Journal of Immunology; 156; 1996; pp. 326-335.
“Chemokines—Chemotactic Cytokines That Mediate Inflammation”; Andrew D. Luster; vol. 338, No. 7; Feb. 12, 1998; pp. 436-445.
“Cyclosporin”;Martindale, The Extra Pharmacopoeia; 31stedition; London, Royal Pharmaceutical Industry; 1996; pp. 557-562.
“Chemokines, lymphocytes and viruses: what goes around, comes around”; P. Nelson, et al.;Curr. Opin., Immunol.; 10, 1998; pp. 265-270.
“Rantes”; P. Nelson, et al.;Cytokines, Handbook of Immunopharmacology Series; London; 1998; pp. 433-448.
“Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6”; R. Nibbs, et al.;The Journal of Biological Chemistry; vol. 272, No. 51; Dec. 19, 1997; pp. 32078-32083.
“Manipulation of Cytokine Networks in Transplantation”; P. Nickerson, et al.;Transplantation; vol. 63, No. 4; Feb. 27, 1997; pp. 489-494.
“The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by chemokines IP10 and Mig”; L. Piali, et al.;Eur. J. Immunol.; 28; 1998; pp. 961-972.
“Effect of CC chemokine receptor anatagonist on collagen induced arthritis in DBA/1 mice”; C. Plater-Zyberk, et al.;Immunology Letters; vol. 57; 1997; pp. 117-120.
“Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist”; A. Proudfoot, et al.;The Journal of Biological Chemistry; vol. 271, vol. 5; Feb. 2, 1996; pp. 2599-2603.
“Chemokines and renal disease”; D. Schlondorff, et al.;Kidney International; vol. 51; 1997; pp. 610-621.
“The cytokine response in renal allograft rejection”; R.L. Schmouder, et al.;Nephrol. Dial. Transplant; 10 [Suppl 1]; 1995; pp. 36-43.
“Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist”; G. Simmons, et al.;Science; vol. 276; Apr. 11, 1997; pp. 276-279.
“Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney”; M. Simon, et al.;Am. J. Physio.; 268; 1995; pp. F240-F250.
“Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm”; T. Springer, et al.;Cell; vol. 76; Jan. 28, 1994; pp. 301-314.
“Enhanced Renal Allograft Rejection by Inhibitors of Nitric Oxide Synthase: A Nonimmunologic Influence of Alloreactivity”; T. Stojanovic, et al.;Laboratory Investigation; vol. 74, No. 2; Feb. 1996; pp. 496-512.
“The Th1/Th2 paradigm and the allograft response”; T. Strom, et al.;Curr. Opin. Immunol.; 8; 1996; pp. 688-693.
“Chemokine-induced Eosinophil Recruitment: Evidence of a Role for Endogenous Eotaxin in an In Vivo Allergy Model in Mouse Skin”; M. Teixeira, et al.;J. Clin. Invest.; vol. 100, No. 7; Oct. 1997; pp. 1657-1666.
“Immunobiology of Renal Transplantation”; J. Valente, et al.;Surgical Clinics of North America; vol. 78, No. 1 Feb. 1998; pp. 1-26.
“RANTES Chemokine Empression in Diseased and Normal Human Tissues”; I. von Leuttichau, et al.;Cytokine; vol. 8, No. 1; Jan. 1996; pp. 89-98.
“Neutrophil Accumulation on Activated, Surface-adherent Platelets in Flow is Mediated by Interaction of Mac-1 with Fibrinogen Bound to α11bβ3 and Stimulated by Platelet-activated Factor”; C. Weber, et al.;J. Clin. Invest.; vol. 100, No. 8; Oct. 1997; pp. 2085-2093.
“Tumor necrosis factor induces enhanced responeses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells”; C. Weber, et al.;Eur. J. Immunol.; 23; 1993; pp. 852-859.
“Inhibitors of Protein Tyrosine Kinase Suppress TNF-Stimulated Induction of Endothelial Cell Adhesion Molecules”; C. Weber, et al.;The Journal of Immunology; 155; 1995; pp. 445-451.
“Monocyte haptotaxis
Grone Hermann-Joseph
Nelson Peter J.
Proudfoot Amanda
Wells Timothy N. C.
Applied Research Systems ARS Holding N.V.
Browdy and Neimark
Hamud Fozia
Mertz Prema
LandOfFree
Chemokine receptor antagonist and cyclosporin in combined... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor antagonist and cyclosporin in combined..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor antagonist and cyclosporin in combined... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495975